{
    "organizations": [],
    "uuid": "3ff8e26ba03c5828cefcbd4ae051ee3919dc9dba",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-nordic-nanovector-says-humalutin-h/brief-nordic-nanovector-says-humalutin-has-shown-significant-tumour-uptake-idUSFWN1RQ0WS",
    "ord_in_thread": 0,
    "title": "BRIEF-Nordic Nanovector Says Humalutin Has Shown Significant Tumour Uptake",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16 (Reuters) - NORDIC NANOVECTOR ASA:\n* POSTER REPORTING ANTI -TUMOUR EFFECT OF HUMALUTIN® (177LU-CONJUGATED HUMANIZED ANTI-CD37 ANTIBODY, 177LU-NNV003) IN PRECLINICAL MODELS OF NON-HODGKIN’S LYMPHOMA (NHL) WAS PRESENTED YESTERDAY\n* COMPANY PREVIOUSLY ANNOUNCED PUBLICATION OF POSTER ABSTRACT (ABSTRACT 848) ON 15 MARCH 2018\n* SAYS HUMALUTIN® HAS SHOWN SIGNIFICANT TUMOUR UPTAKE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-16T13:16:00.000+03:00",
    "crawled": "2018-04-17T12:14:43.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "nordic",
        "nanovector",
        "asa",
        "poster",
        "reporting",
        "anti",
        "effect",
        "humanized",
        "antibody",
        "preclinical",
        "model",
        "lymphoma",
        "nhl",
        "presented",
        "yesterday",
        "company",
        "previously",
        "announced",
        "publication",
        "poster",
        "abstract",
        "abstract",
        "march",
        "say",
        "shown",
        "significant",
        "tumour",
        "uptake",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}